Gene Delivery Using Chemical Methods - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 197

[253] Li S, Huang L. In vivo gene transfer via intravenous administration of cationic lipid-
protamine-DNA (LPD) complexes. Gene Ther 1997;4:891-900.
[254] Li S, Rizzo MA, Bhattacharya S, Huang L. Characterization of cationic lipidprotamine-
DNA (LPD) complexes for intravenous gene delivery. Gene Ther 1998;5:930-7.
[255] Dileo J, Banerjee R, Whitmore M, Nayak JV, Falo LD, Huang L. Lipid-protamine-
DNA-mediated antigen delivery to antigen presenting cells results in enhanced antitu-
mor immune responses. Mol Ther 2003;7:640-8.
[256] Whitmore MM, Li S, Falo LJ, Huang L. Systemic administration of LPD prepared with
CpG oligonucleotides inhibits the growth of established pulmonary metastases by stim-
ulating innate and acquired antitumor immune response. Cancer Immunol Immunother
2001;50:503-14.
[257] Harvie P, Dutzar B, Galbraith T, Cudmore S, O'Mahony D, Anklesaria P, et al. Targeting
of lipid-protamine-DNA (LPD) lipopolyplexes using RGD motifs. J Liposome
Res 2003;13:231-47.
[258] Boulikas T. Nuclear localization signal peptides for the import of plasmid DNA in gene
therapy. Intl J Oncol 1997;10:301-9.
[259] Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules
and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev
2005;57:637-51.
[260] Haralambidis J, Duncan L, Tregear GW. The solid phase synthesis of oligonucleotides
containing a 3-peptide moiety. Tetrahedron Lett 1987;28:5199-202.
[261] Truffert JC, Lorthioir O, Asseline U, Thuong NT, Brack A. On-line solid phase syn-
thesis of oligonucleotide-peptide hybrids using silica supports. Tetrahedron Lett
1994;35:2353-6.
[262] Deshayes S, Gerbal-Chaloin S, Morris MC, Aldrian-Herrada G, Charnet P, Divita G, et
al. On the mechanism of non-endosomial peptide-mediated cellular delivery of nucleic
acids. Biochim Biophys Acta 2004;1667:141-7.
[263] Morris MC, Chaloin L, Mery J, Heitz F, Divita G. A novel potent strategy for gene
delivery using a single peptide vector as a carrier. Nucleic Acids Res 1999;27:3510-17.
[264] Simeoni F, Morris MC, Heitz F, Divita G. Insight into the mechanism of the peptide-
based gene delivery system MPG: implications for delivery of siRNA into mammalian
cells. Nucleic Acids Res 2003;31:2717-24.
[265] Langel U, Pooga M, Kairane C, Zilmer M, Bartfai T. A galanin-mastoparan chimeric
peptide activates the Na  , K()-ATPase and reverses its inhibition by ouabain. Regul
Pept 1996;62:47-52.
[266] Pooga M, Hallbrink M, Zorko M, Langel U. Cell penetration by transportan. FASEB J
1998;12:67-77.
[267] Padari K, Säälik P, Hansen M, Koppel K, Raid R, Langel U, et al. Cell transduction
pathways of transportans. Bioconjugate Chem 2005;16:1399-410.
[268] Muratovska A, Eccles MR. Conjugate for efficient delivery of short interfering RNA
(siRNA) into mammalian cells. FEBS Lett 2004;558:63-8.
[269] Kilk K, El-Andaloussi S, Jaerver P, Meikas A, Valkna A, Bartfai T, et al. Evaluation
of transportan 10 in PEI mediated plasmid delivery assay. J Control Release 2005;103:
511-23.
[270] Ruben S, Perkins A, Purcell R, Joung K, Sia R, Burghoff R, et al. Structural and func-
tional characterization of human immunodeficiency virus tat protein. J Virol 1989;
63:1-8.
[271] Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly trans-
locates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem
1997;272:16010-17.